Cérème 9
| Street Name | Cérème 9 |
| Other Names | CR-9, "Focus Blue", "Exam Glass" |
| Type | Nootropic |
| Source | Synthetic compound (exact origin unknown) |
| Legal Status | Unregulated (under review by Department of Social Security and National Solidarity) |
| Treats | Not medically approved for treatment; used off-label for cognitive enhancement |
| Approved By | No |
| Research Institutions | Unconfirmed ties to Synthalys Biogenetics, Parap |
| Pharmaceutical Company | None officially linked |
| Administration | Oral capsule |
| Frequency of Administration | Once daily (typical user behavior) |
| Uses | Memory recall, cognitive focus, short-term performance enhancement |
| Effects | Improved short-term memory, increased concentration, reduced anxiety under pressure |
| Side Effects | Insomnia, elevated heart rate, mild paranoia, emotional detachment |
| Discovered | Circulated publicly in 1743 AN |
| Discovered By | Unknown (rumored private biotech lab leak) |
Cérème 9 is the street name for an unregulated nootropic substance that gained widespread popularity across Nouvelle Alexandrie in late 1743 AN and 1744 AN, particularly among university students, civil service aspirants, and young professionals. The drug is known for its alleged ability to enhance memory recall, cognitive focus, and short-term learning performance. Despite its growing use, its long-term effects remain unknown and it is not officially approved or classified under any current federal pharmaceutical guidelines.
Origin and Distribution
The precise origins of Cérème 9 remain unclear, though some investigative reporting and academic speculation suggest it may have been developed as a side product of research conducted at Synthalys Biogenetics, a private biomedical firm based in Parap, Wechua Nation. Company officials have denied involvement, stating the compound is not listed in any of its registered or licensed R&D portfolios. The substance is typically distributed in capsule form and is sold in small quantities at university campuses, tech startup hubs, and within select online encrypted platforms. It is not currently available in pharmacies or through legal health providers.
Usage and Effects
Cérème 9 is most commonly consumed orally in capsule form and is often marketed by unofficial vendors as a “cognitive clarity aid” or “academic booster.” Users report heightened ability to retain complex information, better attention during high-stress examinations, and temporary emotional detachment or calm under pressure.
Public and Institutional Response
In early 1744 AN, widespread media attention was drawn to Cérème 9 after a series of articles and news features exposed its increasing use in competitive academic and professional environments.[1] Parents’ groups, school administrators, and some members of the Federal Assembly called for a temporary ban and investigation into its composition, distribution, and long-term effects.
The Department of Social Security and National Solidarity has not officially classified Cérème 9 as a controlled substance but stated in 4.I.1744 AN that it is conducting an "accelerated review" into its biological impacts. No formal clinical trials are known to exist.
Criticism and Controversy
Opponents of the drug argue that it promotes unfair academic and professional advantages, worsens inequality between students with access and those without, and may normalize dependency on enhancement substances. Advocates (mostly among users) argue that Cérème 9 levels the playing field in a society already skewed by structural privilege and elite prep systems.
Some medical professionals have warned that anecdotal evidence points to possible side effects, including elevated heart rate, insomnia, short-term emotional detachment, and mild paranoia. However, no formal adverse event registry exists for the substance.
Legal Status
As of the start of 1744 AN, Cérème 9 is not listed as a banned or scheduled drug in Nouvelle Alexandrie. It remains in a legal gray area, technically not illegal to possess or consume but not recognized for sale under commercial supplement regulations. A proposal to list it as a "substance under provisional review" was introduced in the Federal Assembly in I.1744 AN, but had not passed yet.
See Also
- Department of Social Security and National Solidarity (Nouvelle Alexandrie)
- Education in Nouvelle Alexandrie
- Crisis Generation
- Synthalys Biogenetics
